<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149210</url>
  </required_header>
  <id_info>
    <org_study_id>2019P002286</org_study_id>
    <nct_id>NCT04149210</nct_id>
  </id_info>
  <brief_title>FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial</brief_title>
  <acronym>FLAME</acronym>
  <official_title>FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berhan Public Health and Eye Care Consultancy PLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fred Hollows Foundation, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fred Hollows Foundation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims :&#xD;
&#xD;
        -  To assess the efficacy of fluorometholone 0.1% one drop twice daily for four weeks in&#xD;
           reducing the incidence of post-operative trachomatous trichiasis (TT) when given as&#xD;
           adjunctive therapy with TT surgery in the programmatic setting&#xD;
&#xD;
        -  To assess whether such treatment is sufficiently safe for wide-scale implementation in&#xD;
           TT programs.&#xD;
&#xD;
        -  To estimate the costs of adding fluorometholone 0.1% treatment to TT surgery per case of&#xD;
           postoperative TT averted, and to characterize the value of such treatment under a range&#xD;
           of plausible health economic circumstances&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are pursuing an agenda to evaluate a new potentially cost-effective&#xD;
      approach to improving trichiasis surgery outcomes: perioperative topical anti-inflammatory&#xD;
      therapy. Inflammation-whether induced by the trachoma disease process or surgery itself-most&#xD;
      likely contributes to progressive cicatrization leading to failure of lid rotation surgery in&#xD;
      a clinically important proportion of TT cases. The investigators hypothesize that adjunctive&#xD;
      topical fluorometholone therapy following trichiasis surgery will reduce the risk of&#xD;
      recurrent trichiasis and will be acceptably safe. The rationale for the efficacy aspect of&#xD;
      this hypothesis is that interruption of inflammation postoperatively would reduce&#xD;
      postoperative scarring/contracture driven by ongoing disease-driven inflammation and/or&#xD;
      surgically-induced inflammation thus reducing the incidence of TT recurrence (post-operative&#xD;
      TT) and other inflammation-related outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a 1:1 randomized, double-masked, placebo controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>There will be masking of patients, surgeons and study staff at field site to the assigned treatment group of the subject.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of postoperative TT by one year, as determined by trained study team members</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome measure is the postoperative recurrence of trachomatous trichiasis (TT), defined as one or more eyelashes touching the globe or evidence of epilation (lash stubs) on examination, or a history of repeat trichiasis surgery at any time during the one year follow-up period after the baseline surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Measure 1 - Entropion</measure>
    <time_frame>1 year</time_frame>
    <description>Entropion (presence and extent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Measure 2 - Reoperation</measure>
    <time_frame>1 year</time_frame>
    <description>Reoperation for postoperative TT (recommended or done)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Measure 3 - Lashes</measure>
    <time_frame>1 year</time_frame>
    <description>Number and location of lashes touching the globe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/adverse outcomes 1 - Corneal Opacity</measure>
    <time_frame>1 year</time_frame>
    <description>Corneal opacity (change in proportion from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/adverse outcomes 2 - Overcorrection</measure>
    <time_frame>1 year</time_frame>
    <description>Overcorrection - The surgery rotates the eyelid away from the eyeball (the disease consists of inturning of the eyelid such that the lashes touch the eyeball). Overcorrection would be rotating it away from the globe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/adverse outcomes 3 - Eyelid Abnormalities</measure>
    <time_frame>1 year</time_frame>
    <description>Eyelid notching/eyelid contour abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/adverse outcome 4 - Lid Closure Defect</measure>
    <time_frame>1 year</time_frame>
    <description>Lid closure defect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/adverse outcomes 5 - Granuloma</measure>
    <time_frame>1 year</time_frame>
    <description>Granuloma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/adverse outcomes 7 - IOP in mmHg</measure>
    <time_frame>4 weeks</time_frame>
    <description>IOP elevation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/adverse outcomes 8 - Cataract Surgery</measure>
    <time_frame>1 year</time_frame>
    <description>Occurrence of cataract surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/adverse outcomes - Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events attributed to study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional variables 1 - Visual Acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Visual acuity with presenting correction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2254</enrollment>
  <condition>Trachomatous Trichiasis (TT)</condition>
  <condition>Eye Diseases</condition>
  <condition>Eyelid Diseases</condition>
  <condition>Trachomatous</condition>
  <condition>Trichiasis</condition>
  <arm_group>
    <arm_group_label>fluorometholone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluorometholone 0.1% eyedrops, one drop twice daily for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial Tears</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one drop two times daily for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorometholone 0.1% Oph Susp</intervention_name>
    <description>fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.</description>
    <arm_group_label>fluorometholone</arm_group_label>
    <other_name>FML</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial Tears</intervention_name>
    <description>Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.</description>
    <arm_group_label>Artificial Tears</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 15 years or more, corresponding to the age of patients treated in the Fred Hollows&#xD;
             Foundation/Federal Ministry of Health Program at field sites without general&#xD;
             anesthesia.&#xD;
&#xD;
          2. One or both eyes with upper lid trachomatous trichiasis-with one or more eyelashes&#xD;
             touching the eye or evidence of epilation, in association with tarsal conjunctival&#xD;
             scarring-with a plan to undergo TT surgery on at least one upper eyelid.&#xD;
&#xD;
          3. Collection of all baseline data prior to randomization&#xD;
&#xD;
          4. Signed, informed consent (and assent, when applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication(s) to the use of the test articles, including a known allergy or&#xD;
             sensitivity to the study medication (fluorometholone) or its components, and&#xD;
             contraindication(s) to use of azithromycin&#xD;
&#xD;
          2. IOP≥22 mmHg and/or currently taking more than two ocular anti-hypertensive medications&#xD;
             in the study eye (prior IOP-lowering surgery is acceptable; combinations of two&#xD;
             IOP-lowering agents such as Dorzamol are considered two medications)&#xD;
&#xD;
          3. A known severe / serious ocular pathology or medical condition which may preclude&#xD;
             study completion or increase the risk of harm in the study (e.g., suspicion of&#xD;
             non-trachomatous active ocular infection or suspicion of glaucoma of a degree to which&#xD;
             where an intraocular pressure spike would be vision-threatening).&#xD;
&#xD;
          4. Any condition known to be present at baseline for which it is anticipated ocular or&#xD;
             systemic corticosteroid therapy will be required.&#xD;
&#xD;
          5. Any significant illness or condition (e.g., hypertension with systolic blood&#xD;
             pressure≥170 mmHg and/or diastolic blood pressure≥110 mmHg) that could, in the study&#xD;
             team's opinion, be expected to interfere with the study parameters or study conduct;&#xD;
             or put the subject at significant risk.&#xD;
&#xD;
          6. Previous upper lid TT surgery on all eyes with upper lid TT. (If one eye has&#xD;
             previously undergone upper lid TT surgery but another eye with upper lid TT has not,&#xD;
             the patient may be enrolled, and only the latter eye will be counted for the primary&#xD;
             analyses).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H Kempen, MD MPH MHS PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts Eye and Ear Infirmary/Harvard Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John H Kempen, MD MPH MHS PhD</last_name>
    <phone>617-573-3202</phone>
    <phone_ext>7812480294</phone_ext>
    <email>John_Kempen@MEEI.HARVARD.EDU</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tony Succar, PhD MScMed(OphthSc)</last_name>
    <phone>6175734436</phone>
    <phone_ext>7812480294</phone_ext>
    <email>tony_succar@meei.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ministry of Science and Higher Education Ethiopia</name>
      <address>
        <city>Addis Ababa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 12, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>John Harold Kempen</investigator_full_name>
    <investigator_title>Professor, Director of Epidemiology for Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>fluorometholone 0.1%</keyword>
  <keyword>trachomatous trichiasis</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Eyelid Diseases</keyword>
  <keyword>trachomatous</keyword>
  <keyword>trichiasis</keyword>
  <keyword>FLAME</keyword>
  <keyword>TT Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Trichiasis</mesh_term>
    <mesh_term>Eyelid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorometholone</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Per National Institutes of Health policy at the time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

